

April 24, 2026
JCR Pharmaceuticals Co., Ltd.

Notice of Election of Candidate for New Outside Director

Hyogo, Japan – April 24, 2026 – [JCR Pharmaceuticals Co., Ltd.](http://www.jcr-pharm.co.jp) (TSE 4552; “JCR”) today announced that its Board of Directors resolved at a meeting held today to nominate the following candidate for its Board of Director, to be proposed for election at the Ordinary General Meeting of Shareholders scheduled to be held on June 23, 2026. Appointments will be subject to approval at the Ordinary General Meeting of Shareholders.

1. Candidate for New Board of Directors

Name	Title
Toshio Asano	Outside Director (Independent)

2. Brief personal histories of candidates for Board of Directors

[Name]	Toshio Asano
[Date of Birth]	December 4, 1952
[Brief biography]	
October 2003	Executive Officer of Asahi Kasei Pharma Corporation
April 2008	Director and Managing Executive Officer of Asahi Kasei Pharma Corporation
April 2010	President and Chief Executive Officer of Asahi Kasei Pharma Corporation
April 2011	Executive Officer of Asahi Kasei Corp.
April 2014	Presidential Executive Officer of Asahi Kasei Corp.
June 2014	President & Representative Director of Asahi Kasei Corp.
April 2016	Director of Asahi Kasei Corp.
June 2016	Permanent Consultant of Asahi Kasei Corp.
June 2017	Outside Director of Medipal Holdings Corporation (to present)
June 2019	Outside Director of Daicel Corporation (to present)
June 2019	Outside Director of Tokyo Century Corporation (to present)
January 2020	Special Advisor of the Company (to present)
June 2021	Chairman of Japanese Foundation for Cancer Research (to present)
June 2024	Special Advisor of Asahi Kasei Corp. (to present)

New Executive and Board Leadership Structure (After June 23, 2026)

• Representative Director

Representative Director, Chairman	Toru Ashida
Representative Director, President, Chief Scientific Officer	Hiroyuki Sonoda, Ph.D.

• Director

Director, Senior Managing Executive Officer, Development Division	Andrea Spezzi, M.D., FFPM
Director, Managing Executive Officer, Executive Director, Quality Assurance Division	Yoshio Hiyama, Ph.D.

• Founder

Director, Founder	Shin Ashida
-------------------	-------------

• Outside Director

Director (Independent)	Takashi Suetsuna
Director (Independent)	Yuko Hayashi, Ph.D.
Director (Independent)	Yutaka Atomi, M.D., Ph.D.
Director (Independent)	Philippe Fauchet, OBE
Director (Independent)	Toshio Asano
Director	Marc Dunoyer
Director	Toshihide Yoda

• Outside Audit & Supervisory Board Member

Full-Time Independent Audit & Supervisory Board Member (Independent)	Kazumasa Oizumi
Independent Audit & Supervisory Board Member (Independent)	Masayuki Mitsuka
Independent Audit & Supervisory Board Member (Independent)	Miya Miyama

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###